Archive

Lamina to release 4 new products at the CWIEME Berlin trade show.

May 30, 2014

After carefully listening to customer feedback, Lamina has spent the last year in R&D developing 4 new products to hit key applications which will be released at CWIEME Berlin. Lamina has been supplying the tubular insulation industry for over 40 years and is still the leading innovator in the field.

Lamina’s innovations are aimed at helping our customers to improve efficiency, increase quality and simplify manufacture:

Contech tube– Lamina’s new continuous layflat tube without joins is available on reels for a continuous feed - simplifying manufacture at a good value proposition. A perfect fit for noise reduction of washing machine rotors.

Triple Endcap– Lamina’s patented answer for rapid application of 3 caps in 1 and reducing exposure to RSI and related costs. Meeting the needs of hermetic compressor manufacturers.

Heat Shrinkable Epoxy Tubing– Combining the bonding strength of epoxies with heat shrink capabilities of Plamar for rapid and simple securing of components. Ideal solution for easy bonding of magnets in brushless motors and offering a route towards a waterproof seal.

Epoxy Woven Glass Spiral Wound Tubes – the ultimate strength for demanding applications.

To find out more come and visit us on stand 42A89, hall number 4.2. at http://www.coilwindingexpo.com/berlin/

On contact us at .(JavaScript must be enabled to view this email address)

Lamina are pleased to announce the next stage in the development of its patented capillary film technology.

May 29, 2014

Lamina are pleased to announce the next stage in the development of its patented capillary film technology. Lamina will be supplying film to Capillary Film Technology Limited (CFT) to develop products to meet the needs of NHS patients, after winning  £98K funding for dev. of POC acute coronary syndrome diagnostic.

CFT, a technology and product development company for life sciences and clinical diagnostics, today announced it has received £98K in funding as part of a Small Business Research Initiative for Healthcare (SBRI Healthcare) development contract. The funding will be used to develop a cost-effective and fully quantitative multiplexed point-of-care (POC) testing technology to aid in the assessment of acute coronary syndrome.

The POC diagnostic is based on CFT’s FluorEx™ technology, a low-cost microfluidic fluoropolymer film that possesses unique optical transparency. FluorEx uses a parallel array of 10 x 200 micron capillaries to enable rapid fully quantitative immunoassays to be incorporated in existing or emergent diagnostic technologies. The technology has the potential to provide a cost effective quantitative option for diagnosing acute coronary syndrome, resulting in reduced waiting times and improved treatment for patients. CFT’s FluorEx technology is available for licensing.

Commenting on the funding, Dr Lee Smith, CEO at CFT, said: “Our vision is to develop a next-generation lateral flow diagnostic testing technology that can measure multiple clinically relevant biomarkers, such as those used to select treatments for patients presenting with symptoms of acute cardiac syndrome, but with the low cost and simplicity required by emergency medics, paramedics, and GPs. This funding will enable us to focus on developing a diagnostic technology that meets the specific needs of NHS patients, and ultimately improve the health of patients suffering from heart attacks.”

Read more about the technology at http://www.capfilmtech.com/